New Study in Clinical Cancer Research Demonstrates Potential for Cyclacel’s Seliciclib in Treating Breast Cancer …
New Study in Clinical Cancer Research Demonstrates Potential for Cyclacel’s Seliciclib in Treating Breast Cancer …
BERKELEY HEIGHTS, N.J. — Cyclacel Pharmaceuticals, Inc. today announced that a newly published study demonstrates that the company’s seliciclib , an orally available inhibitor of multiple cyclin-dependent kinases , reversed resistance to the aromatase inhibitor letrozole and killed hormone receptor positive breast cancer cells that had become insensitive to the effects of letrozole. The new …
Read more on GlobeNewswire via Yahoo! Finance
Categories: Breast Cancer Research Tags: breast, cancer, Clinical, Cyclacel's, Demonstrates, Potential, research, Seliciclib, Study, Treating
Immunovaccine Announces Preliminary Safety Results from Phase I Clinical Trial of DPX-0907 Cancer Vaccine
Immunovaccine Announces Preliminary Safety Results from Phase I Clinical Trial of DPX-0907 Cancer Vaccine
HALIFAX, NOVA SCOTIA–(Marketwire – Dec. 14, 2010) – Immunovaccine Inc. (TSX VENTURE:IMV) today announced preliminary safety results for its Phase I clinical trial of DPX-0907, a DepoVaxT-based therapeutic cancer vaccine candidate for the treatment of patients with advanced stage breast, ovarian or prostate cancer. In this trial, patients receive three subcutaneous injections of either 0.25 mL …
Read more on Marketwire
Categories: Breast Cancer Treatment Tags: Announces, cancer, Clinical, DPX0907, From, Immunovaccine, Phase, Preliminary, Results, Safety, Trial, vaccine
BioAlliance presents AMEP preclinical, phase I clinical results for melanoma at Electrochemotherapy Meeting
BioAlliance presents AMEP preclinical, phase I clinical results for melanoma at Electrochemotherapy Meeting
BioAlliance Pharma SA, a company dedicated to the supportive care and treatment of cancer patients, presented preclinical and promising preliminary phase I clinical results with its AMEP biotherapy at the “Electrochemotherapy 1st International Users’ Meeting”(Bologna, Italy, November 19-20, 2010).
Read more on News-Medical-Net
Categories: Breast Cancer Pain Tags: AMEP, BioAlliance, Clinical, Electrochemotherapy, Meeting, Melanoma, Phase, preclinical, presents, Results
Cylene To Present Advances With Industry’s Only Clinical CK2 Inhibitor, CX-4945, At EORTC-NCI-AACR
Cylene To Present Advances With Industry’s Only Clinical CK2 Inhibitor, CX-4945, At EORTC-NCI-AACR
Cylene Pharmaceuticals, Inc. will present advances in the development of their first-in-class, CK2 inhibitor CX-4945, at the 22nd EORTC-NCI-AACR symposium on Molecular Targets and Cancer Therapeutics, to be held on November 16-19 in Berlin, Germany. CX-4945 is the first and only CK2 inhibitor to have entered clinical trials and represents an exciting new approach for the treatment for many …
Read more on Medical News Today
Categories: Breast Cancer Tumor Tags: Advances, Clinical, CX4945, Cylene, EORTCNCIAACR, Industry's, Inhibitor, only, present
S*BIO’s SB1317 enters Phase 1 clinical trial in patients with advanced/refractory hematologic malignancies
S*BIO’s SB1317 enters Phase 1 clinical trial in patients with advanced/refractory hematologic malignancies
S*BIO Pte Ltd today announced that a fourth novel, potential best-in-class compound discovered and developed by S*BIO has entered a Phase 1 clinical trial. The initiation of the study for S*BIO’s oral multi-kinase inhibitor, SB1317 or TG02, in patients with advanced/refractory hematologic malignancies has triggered a payment from S*BIO’s development and commercialization partner for the program …
Read more on News-Medical-Net
Categories: Breast Cancer Treatment Tags: advanced/refractory, Clinical, Enters, hematologic, malignancies, Patients, Phase, S*BIO's, SB1317, Trial